Published in Drug Dev Ind Pharm on November 08, 2006
Effective modification of particle surface properties using ultrasonic water mist. AAPS PharmSciTech (2009) 0.85
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol (2013) 4.78
Abeta40 inhibits amyloid deposition in vivo. J Neurosci (2007) 2.47
Isolated gastrocnemius tightness. J Bone Joint Surg Am (2002) 1.93
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst (2010) 1.44
The effects of age on medio-lateral stability during normal and narrow base walking. Gait Posture (2008) 1.42
Virtual Sensorimotor Training for Balance: Pilot Study Results for Children With Fetal Alcohol Spectrum Disorders. Pediatr Phys Ther (2016) 1.40
Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. Respirology (2013) 1.38
An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol (2012) 1.28
Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers. AAPS J (2012) 1.20
Pushrim biomechanics and injury prevention in spinal cord injury: recommendations based on CULP-SCI investigations. J Rehabil Res Dev (2005) 1.18
Effect of balance training on recovery of stability in children with cerebral palsy. Dev Med Child Neurol (2003) 1.18
Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology (2011) 1.17
Cell patterning: interaction of cardiac myocytes and fibroblasts in three-dimensional culture. Microsc Microanal (2008) 1.12
Shoulder biomechanics during the push phase of wheelchair propulsion: a multisite study of persons with paraplegia. Arch Phys Med Rehabil (2008) 1.10
The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations. Pharm Res (2008) 1.10
Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics (2007) 1.07
Age-associated effects of a concurrent cognitive task on gait speed and stability during narrow-base walking. J Gerontol A Biol Sci Med Sci (2008) 1.04
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2007) 1.03
The influence of dose on the performance of dry powder inhalation systems. Int J Pharm (2005) 1.01
Redefining the manual wheelchair stroke cycle: identification and impact of nonpropulsive pushrim contact. Arch Phys Med Rehabil (2009) 1.01
Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv (2014) 0.98
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm (2008) 0.98
The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics. Pharm Res (2004) 0.98
The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm Res (2004) 0.96
An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces. Pharm Res (2007) 0.96
Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm (2010) 0.93
Age and features of movement influence motor overflow. J Am Geriatr Soc (2003) 0.93
Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. Pharm Res (2012) 0.93
The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res (2006) 0.92
The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J Pharm Sci (2008) 0.92
Motor cortex activation is preserved in patients with chronic hemiplegic stroke. Ann Neurol (2002) 0.92
An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. Eur J Pharm Biopharm (2007) 0.92
Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat (2011) 0.92
The association between obstructive sleep apnea syndrome and microvascular complications in well-controlled diabetic patients. Mil Med (2010) 0.91
Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res (2010) 0.90
Effect of balance training on muscle activity used in recovery of stability in children with cerebral palsy: a pilot study. Dev Med Child Neurol (2005) 0.89
Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res (2012) 0.89
Target localization for post-prostatectomy patients using CT and ultrasound image guidance. J Appl Clin Med Phys (2005) 0.89
Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv (2009) 0.89
Pharmaceutical characterisation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer. Int J Pharm (2013) 0.88
Multisite comparison of wheelchair propulsion kinetics in persons with paraplegia. J Rehabil Res Dev (2007) 0.88
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: influence of polymer concentration on physical and in vitro characteristics. Eur J Pharm Biopharm (2007) 0.87
Micro-particle corrugation, adhesion and inhalation aerosol efficiency. Eur J Pharm Sci (2008) 0.86
Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems. J Pharm Sci (2011) 0.86
The use of computational approaches in inhaler development. Adv Drug Deliv Rev (2011) 0.86
The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. AAPS PharmSciTech (2004) 0.86
Locomotor training using body-weight support on a treadmill in conjunction with ongoing physical therapy in a child with severe cerebellar ataxia. Phys Ther (2007) 0.86
Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation. Int J Pharm (2012) 0.86
Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers. AAPS J (2015) 0.85
Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv (2011) 0.85
The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Drug Dev Ind Pharm (2008) 0.85
Sensory control of balance: a comparison of children with fetal alcohol spectrum disorders to children with typical development. J Popul Ther Clin Pharmacol (2013) 0.84
Health care providers' perspectives of an intervention designed to improve colorectal cancer screening rates in family medicine residency clinics : a qualitative study. J Cancer Educ (2012) 0.84
Dynamic vapor sorption properties of sodium starch glycolate disintegrants. Pharm Dev Technol (2005) 0.84
Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. J Pharm Biomed Anal (2009) 0.84
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci (2010) 0.84
Particulate production during orthodontic production laboratory procedures. J Expo Sci Environ Epidemiol (2011) 0.83
Prostate bed motion during intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys (2012) 0.83
Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J Pharm Sci (2008) 0.83
Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach. J Pharm Sci (2006) 0.83
Recent advances in controlled release pulmonary therapy. Curr Drug Deliv (2009) 0.83
Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). Eur J Pharm Sci (2009) 0.83
The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci (2007) 0.82
Characterisation and functionality of inhalation anhydrous lactose. Int J Pharm (2010) 0.82
Factors affecting defining the quality and functionality of excipients used in the manufacture of dry powder inhaler products. Drug Dev Ind Pharm (2008) 0.82
Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci (2008) 0.82
On the physical transformations of processed pharmaceutical solids. Micron (2005) 0.82
Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference. Ann Surg Oncol (2015) 0.81
Visualization of the crystallization of lactose from the amorphous state. J Pharm Sci (2004) 0.81
Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: an AFM and Raman investigation. J Colloid Interface Sci (2011) 0.81
Dehydration of trehalose dihydrate at low relative humidity and ambient temperature. Int J Pharm (2006) 0.81
Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. Int J Pharm (2011) 0.81
The effect of mechanical processing on surface stability of pharmaceutical powders: visualization by atomic force microscopy. J Pharm Sci (2003) 0.81
Pharmaceutical applications of the Calu-3 lung epithelia cell line. Expert Opin Drug Deliv (2013) 0.81
Effect of humidity on aerosolization of micronized drugs. Drug Dev Ind Pharm (2003) 0.81
The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. Eur J Pharm Sci (2004) 0.81
An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations. AAPS PharmSciTech (2014) 0.80
Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia. Mol Pharm (2012) 0.80
Influence of particle size and shape on flowability and compactibility of binary mixtures of paracetamol and microcrystalline cellulose. Eur J Pharm Sci (2004) 0.80
Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique. Pharm Res (2004) 0.80
Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J Pharm Sci (2009) 0.80
Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems. J Pharm Sci (2011) 0.80
Non-cytotoxic silver nanoparticle-polyvinyl alcohol hydrogels with anti-biofilm activity: designed as coatings for endotracheal tube materials. Biofouling (2014) 0.80
Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model. Antimicrob Agents Chemother (2013) 0.80
Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy. Int J Pharm (2012) 0.79
Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers. Ther Deliv (2013) 0.79
Engineering of crystalline combination inhalation particles of a long-acting beta2-agonist and a corticosteroid. Pharm Res (2009) 0.79
Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases. AAPS J (2014) 0.79
Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations. Drug Dev Ind Pharm (2006) 0.79